Amonafide
 | |
| Clinical data | |
|---|---|
| Trade names | Xanafide, Quinamed |
| ATC code | none |
| Identifiers | |
| |
| CAS Number | 69408-81-7 |
| PubChem (CID) | 50515 |
| ChemSpider |
45804  |
| UNII |
1Q8D39N37L |
| KEGG |
D10090 |
| ChEMBL |
CHEMBL428676 |
| Chemical and physical data | |
| Formula | C16H17N3O3 |
| Molar mass | 283.325 g/mol |
| 3D model (Jmol) | Interactive image |
| |
| |
| (verify) | |
Amonafide (originally AS1413) (INN, trade names Quinamed and Xanafide) is a drug that is being studied in the treatment of cancer. It belongs to a novel family of chemotherapeutic drugs called Naphthalimides and is a potential topoisomerase inhibitor and DNA intercalator.
It is being developed as an anti-cancer therapy by Antisoma.[1]
As of 2008, it is in Phase III clinical trials. e.g. In March 2010 it is Phase III trial against secondary acute myeloid leukaemia (AML).[2] In June 2010, it gained an FDA Fast Track Status for the treatment of Secondary Acute Myeloid Leukaemia.
See also
References
- ↑ http://www.genengnews.com/news/bnitem.aspx?name=78979622
- ↑ http://clinicaltrials.gov/ct2/show/NCT00715637 "Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDE Study"
External links
- Amonafide entry in the public domain NCI Dictionary of Cancer Terms
- Clinical trials of amonafide at ClinicalTrials.gov
This article incorporates public domain material from the U.S. National Cancer Institute document "Dictionary of Cancer Terms".
This article is issued from Wikipedia - version of the 6/7/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.